-
公开(公告)号:US20240124450A1
公开(公告)日:2024-04-18
申请号:US18466034
申请日:2023-09-13
Applicant: Pfizer Inc.
Inventor: Andrea Nicole Bootsma , David Christopher Ebner , Daniel Wei-Shung Kung , Matthew Alexander Perry , Daniel Copley Schmitt , Joseph Walter Strohbach , Atli Thorarensen
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: A compound of formula I having the structure:
or a pharmaceutically acceptable salt thereof, wherein A1 and A2 are independently O or S; X is selected from CH2, CD2, NR3, O, and S, where R3 is selected from hydrogen, C1-C4 linear or branched chain alkyl, halo(C1-C4)linear or branched chain alkyl, and hydroxyl(C1-C4)linear or branched chain alkyl; Y and Z are selected from C and N, where when Y is C, then Z is N, and when Y is N, then Z is C; R1 and R2 are independently selected from hydrogen, deuterium, C1-C4 linear or branched chain alkyl, etc.; or a C1-C2 alkyl substituted with a C3-C5 cycloalkyl ring; or taken together to form a C3-C6 cycloalkyl ring; or where X is CH2 or CD2, then R1 and R2 are independently selected from hydrogen, deuterium, halogen, hydroxyl, C1-C4 linear or branched chain alkyl, etc.; R4 is selected from hydrogen, deuterium, cyano, halogen, (C1-C3) alkoxy, etc.; R5 is selected from hydrogen, deuterium, halogen, C1-C3 alkoxy, amino, (C1-C4 linear or branched chain alkyl)amino, etc.; R6 is selected from hydrogen, deuterium, halogen, CO2R7 where R7 is selected from H and C1-C4 linear or branched chain alkyl, etc.; R8 is selected from hydrogen, deuterium, and C1-C3 linear or branched chain alkyl; R9 is selected from C1-C3 linear or branched chain alkyl, and a halo(C1-C3)linear or branched chain alkyl; and, n and m are independently selected from 0, 1 and 2. The invention also relates to pharmaceutical compositions thereof and therapeutic methods of use therewith.-
公开(公告)号:US20240336572A1
公开(公告)日:2024-10-10
申请号:US18626467
申请日:2024-04-04
Applicant: Pfizer Inc.
Inventor: Samit Kumar Bhattacharya , Edward Lee Conn , David Christopher Ebner , Brian Stephen Gerstenberger , Chan Woo Huh , Daniel Wei-Shung Kung , Alan Martin Mathiowetz , Jessica Gloria Katherine O'Brien , Meihua Mike Tu , Kimberly O'Keefe Cameron , Dilinie Prasadhini Fernando , Kevin James Filipski , Esther Cheng Yin Lee , Sarah Jane Mear , Aaron Christopher Smith
IPC: C07D231/56 , A61K31/416
CPC classification number: C07D231/56 , A61K31/416
Abstract: The invention relates to substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.
-
公开(公告)号:US20160016940A1
公开(公告)日:2016-01-21
申请号:US14773954
申请日:2013-09-24
Applicant: PFIZER INC.
Inventor: Samit Kumar Bhattacharya , Kimberly O'Keefe Cameron , Matthew Scott Dowling , David Christopher Ebner , David James Edmonds , Dilinie Prasadhini Fernando , Kevin James Filipski , Daniel Wei-Shung Kung , Esther Cheng Yin Lee , Aaron Christopher Smith , Meihua Mike Tu
IPC: C07D405/12 , C07D401/12 , C07D403/12 , C07D401/04
CPC classification number: C07D405/12 , A61K31/4439 , C07D401/04 , C07D401/12 , C07D403/12
Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶(AMPK)的式(I)的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病,病症或障碍的方法。
-
公开(公告)号:US09394285B2
公开(公告)日:2016-07-19
申请号:US14773954
申请日:2013-09-24
Applicant: Pfizer Inc.
Inventor: Samit Kumar Bhattacharya , Kimberly O'Keefe Cameron , Matthew Scott Dowling , David Christopher Ebner , David James Edmonds , Dilinie Prasadhini Fernando , Kevin James Filipski , Daniel Wei-Shung Kung , Esther Cheng Yin Lee , Aaron Christopher Smith , Meihua Mike Tu
IPC: C07D405/12 , C07D403/12 , C07D401/04 , C07D401/12 , A61K31/404 , A61K31/4439 , A61K31/454 , A61K31/496 , A61P13/12 , A61P3/10
CPC classification number: C07D405/12 , A61K31/4439 , C07D401/04 , C07D401/12 , C07D403/12
Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶(AMPK)的式(I)的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病,病症或障碍的方法。
-
-
-